Written question asked by Lord Warner (Crossbench) on Monday, 19 June 2023, in the House of Lords. It was due for an answer on Monday, 3 July 2023. It was answered by Lord Markham (Conservative) on Tuesday, 27 June 2023 on behalf of the Department of Health and Social Care.

Voluntary Scheme for Branded Medicines Pricing and Access

Question: To ask His Majesty's Government what assessment they have made of whether the Voluntary Scheme for Branded Medicines Pricing and Access has caused a reduction in the supply of biosimilar medicines, and any associated impact on (1) patient outcomes, (2) NHS finances in the short term, and (3) the ability to make cost-savings in the longer term.

Answer: The Department recognises the important role that biosimilars and generics play in ensuring affordability, patient access, and supply resilience. We have not seen convincing evidence that the voluntary scheme for branded medicines pricing and access has had an impact on medicines supply including biosimilars, given available mitigations such as provisions in the scheme for companies to apply for price increases should supply of products be otherwise uneconomical.

Secondary information

Type: Written question
Reference: HL8633
Session: 2022-23
Related items: Life Sciences: Foreign Investment in UK
Tuesday, 25 July 2023
Written questions
House of Lords; Voluntary Scheme for Branded Medicines Pricing and Access
Tuesday, 25 July 2023
Written questions
House of Lords; Life Sciences: Foreign Investment in UK
Tuesday, 25 July 2023
Written questions
House of Lords; Voluntary Scheme for Branded Medicines Pricing and Access
Tuesday, 25 July 2023
Written questions
House of Lords
Subjects: Drugs Generic prescribing Voluntary scheme for branded medicines pricing and access
Link: View this Written question on www.parliament.uk